Partnerships
Page 1 • 3 itemsDiscover global pharma partnerships driving innovation and market growth. Essential intelligence for BD, investors, and analysts.
Purdue Pharma Shutdown: $7.4B Deal Ends OxyContin Maker's Operations
Purdue Pharma, the manufacturer of OxyContin, is ceasing operations following a $7.4 billion settlement agreement. This landmark deal aims to address the company's role in the opioid crisis and provide compensation to victims.
Purdue Pharma Shutdown: $7.4B Deal Ends OxyContin Maker's Era
Purdue Pharma, the manufacturer of OxyContin, is ceasing operations as part of a $7.4 billion settlement to address its role in the opioid crisis. This landmark agreement aims to resolve thousands of lawsuits and redirect company assets towards addiction treatment and prevention.
Oncotelic Therapeutics Updates Partnership Strategy for Cancer Drug Development Pipeline
Oncotelic Therapeutics provides corporate update on strategic partnerships to advance clinical-stage cancer treatments and expand market reach.